Genmab AS Net Income Per E B T Over Time
| GMAB Stock | USD 20.75 0.80 3.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Genmab AS Performance and Genmab AS Correlation. Genmab |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Per E B T Analysis
Compare Genmab AS and related stocks such as Ascendis Pharma AS, Apellis Pharmaceuticals, and BeiGene Net Income Per E B T Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASND | 0.9728 | 0.9728 | 0.9728 | 0.867 | 0.934 | 0.9806 | 0.9967 | 0.9962 | 0.997 | 0.9989 | 0.9995 | 0.999 | 1.0093 | 1.0154 | 0.78 |
| APLS | 0.9605 | 0.9605 | 0.9605 | 0.9605 | 0.9605 | 1.0168 | 1.0168 | 1.0168 | 1.0168 | 1.0168 | 1.0054 | 1.0005 | 1.001 | 1.004 | 0.8 |
| BGNE | 0.9493 | 0.9493 | 0.9493 | 0.9493 | 0.9855 | 1.0005 | 1.0005 | 1.0224 | 0.9767 | 1.0074 | 0.9891 | 0.9825 | 1.0218 | 1.0677 | 0.8 |
| AKRO | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9998 | 0.9996 | 0.9721 | 1.12 | 1.09 |
| BPMC | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9966 | 1.0047 | 1.0095 | 1.0019 | 0.79 |
| DAWN | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.8662 | 0.9239 | 0.9682 | 0.9296 | 0.84 | 0.74 |
| TERN | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9793 | 0.9997 | 1.0204 | 1.0102 | 1.006 | 1.0027 | 0.8 |
| LEGN | 0.6768 | 0.6768 | 0.6768 | 0.6768 | 0.6768 | 0.6768 | 0.6768 | 0.6768 | 1.7228 | 1.02 | 0.9865 | 1.0 | 1.0014 | 0.9964 | 1.17 |
| PCVX | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 1.0641 | 0.9843 | 1.0001 | 1.0723 | 0.97 | 0.82 |
| TVTX | 1.0022 | 1.0022 | 1.0022 | 1.0022 | 0.9783 | 1.1116 | 0.8319 | 1.0234 | 1.008 | 0.9999 | 0.8975 | 1.0023 | 1.0011 | 0.2962 | 0.28 |
| ALEC | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9471 | 0.9618 | 0.7711 | 1.025 | 1.0416 | 0.76 |
| CYTK | 0.9939 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2248 | 1.2895 | 1.1257 | 1.035 | 0.93 | 0.89 |
| EWTX | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.9774 | 0.996 | 0.9843 | 0.793 | 0.91 | 1.03 |
Genmab AS and related stocks such as Ascendis Pharma AS, Apellis Pharmaceuticals, and BeiGene Net Income Per E B T description
My Equities
My Current Equities and Potential Positions
Check out Genmab AS Performance and Genmab AS Correlation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.